TICKERNERD
Menu
USPHUSPHHealthcare · Medical Care Facilities

USPH Stock Forecast: U.S. Physical Therapy, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$85
−0.62% on the day

The 7 Wall Street analysts covering U.S. Physical Therapy, Inc. hold a median 12-month price target of $97 — +14.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$1.3B
Ticker Nerd rank
57 / 100
Median analyst target
$97
Analysts covering
7
Revenue$214.1M+8.5% y/y
Operating income$22.9M
Net income$14.9M
Free cash flow$29.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
+5.5%
YTD
+10.8%
1Y
−4.3%
From 52W high
−6.5%
From 52W low
+45.8%
$58
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

USPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores U.S. Physical Therapy, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
79
Momentum
68
Accruals
66
Value
57
Growth
56
Revisions
50
Issuance
46
Quality
45
Size
40

Volatility (79): The share price has been relatively steady.

Quality (45): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

USPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on USPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100Jan 26Apr 26Jul 26Oct 26USPHHigh $100Median $97Low $95

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $95Median $97High $100

The green dot is the last close — the median target sits +14.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Sept 2026JP MorganMaintainsOverweight$90 → $95
10 Aug 2026Barrington ResearchMaintainsOutperform—
10 Aug 2026Barrington ResearchMaintainsOutperform$90 → $98
24 June 2026CitizensReiteratesMarket Outperform—
24 June 2026CitizensReiteratesMarket Outperform$98
13 May 2026Barrington ResearchMaintainsOutperform—
8 May 2026CitizensMaintainsMarket Outperform—
10 Mar 2026JefferiesAssumesBuy$102
20 Feb 2026Barrington ResearchMaintainsOutperform—
5 Jan 2026Barrington ResearchMaintainsOutperform—
24 Nov 2025JP MorganMaintainsOverweight—
24 Oct 2025Barrington ResearchMaintainsOutperform—
18 Sept 2025JP MorganAssumesOverweight$110
8 Aug 2025Barrington ResearchMaintainsOutperform—
1 July 2025Barrington ResearchMaintainsOutperform—
22 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
19 Mar 2025JP MorganMaintainsOverweight—
28 Feb 2025Barrington ResearchMaintainsOutperform—
16 Dec 2024B of A SecuritiesUpgradeBuy—
16 Dec 2024JMP SecuritiesInitiatesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. USPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

USPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, U.S. Physical Therapy, Inc. returned −4.3% against +17.5% for the S&P 500, dividends included.

USPH vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26USPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

USPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.2%
Analysts raising
1
Analysts cutting
0
Fundamentals

U.S. Physical Therapy, Inc. (USPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
474.7×

Cheaper than 2% of US stocks

Price / sales
1.6×

Cheaper than 57% of US stocks

Price / book
2.8×

Cheaper than 32% of US stocks

EV / EBITDA
19.2×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
8.5%

Higher than 48% of US stocks

Earnings growth (YoY)
−20.1%

Higher than 21% of US stocks

Gross margin
19.6%

Higher than 20% of US stocks

Operating margin
11.1%

Higher than 66% of US stocks

Net margin
4.0%

Higher than 58% of US stocks

Returns & dividend
Return on equity
6.5%

Higher than 56% of US stocks

Return on assets
4.1%

Higher than 71% of US stocks

Dividend yield
2.2%

Higher than 80% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

U.S. Physical Therapy, Inc. (USPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • U.S. Physical Therapy, Inc. has a market value of $1.3B and an enterprise value of $2.0B.

  • Revenue in the twelve months to 30 June 2026: $812.2M. The latest quarter grew 8.5% year on year.

  • Net income over the same four quarters: $49.9M, a 6.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.17.

  • Free cash flow in the twelve months to 30 June 2026: $64.1M.

  • Shares outstanding: 14.9M.

  • Trailing P/E: 474.7×; forward P/E: 25.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.15%, paying out 1011% of earnings.

  • U.S. Physical Therapy, Inc. employs 4,653 people — $175K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

USPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
USPHU.S. Physical Therapy, Inc.$1.3B
57
INNVInnovAge Holding Corp.$1.2B
98
NUTXNutex Health, Inc.$1.4B
88
PNTGThe Pennant Group, Inc.$1.4B
72
AGLAgilon Health, Inc.$1.5B
70
AMNAMN Healthcare Services, Inc.$1.5B
100
HCSGHealthcare Services Group, Inc.$1.5B
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own U.S. Physical Therapy, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest USPH news & analysis

U.S. Physical Therapy Announces the Appointment of New Board Member Myra Davis

Business Wire · 21 Sept 2026neutral

U.S. Physical Therapy, Inc. announced that its Board of Directors approved the appointment of Myra Davis as a new board member, effective October 1, 2026. Davis currently serves as Executive Vice President and Chief Information Innovation Officer at Texas Children's.

Why it matters — USPH watchers would note the board's addition of an executive with leadership experience at a major children's healthcare organization.

U.S. Physical Therapy Bets on Hospital Alliances to Drive Visits, Reimbursement

MarketBeat · 27 Aug 2026positive

U.S. Physical Therapy (NYSE: USPH) is pursuing growth through clinic openings, acquisitions, and a newer hospital-alliance strategy. CEO Chris Reading said this approach could expand patient volumes and improve reimbursement.

Why it matters — USPH watchers would care because hospital alliances represent a new growth lever that could influence both patient traffic and reimbursement rates for the company.

U.S. Physical Therapy Presented at the 17th Annual Midwest Ideas Conference

Business Wire · 27 Aug 2026neutral

U.S. Physical Therapy announced that its Chairman and CEO, Chris Reading, presented at the 17th Annual Midwest Ideas Conference on August 26, 2026. The presentation covered the healthcare operating environment, the Company's key initiatives, and related topics.

Why it matters — USPH watchers would care because the presentation offered investors and analysts direct insight into the Company's strategic initiatives and its view of the broader healthcare operating environment.

U.S. Physical Therapy Announces CFO

Business Wire · 14 Aug 2026neutral

U.S. Physical Therapy announced that Nchacha Etta will serve as Executive Vice President and Chief Financial Officer, effective September 1, 2026. Since April 24, 2026, Jason Curtis had served as Interim CFO.

Why it matters — A USPH watcher would care because the company has formally filled the CFO role, resolving interim leadership and setting future financial management direction.

U.S. Physical Therapy Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026neutral

U.S. Physical Therapy reported second-quarter 2026 revenue growth driven by higher patient volumes, improved reimbursement rates, and early rollout of hospital-affiliation agreements. However, elevated employee healthcare claims and upfront staffing costs pressured physical therapy margins.

Why it matters — USPH watchers would care because the quarter reflects both revenue growth drivers and margin pressures that could shape the company's near-term performance.

FAQ

Frequently asked questions about USPH stock

What is the USPH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering U.S. Physical Therapy, Inc. have a median 12-month price target of $97, with estimates ranging from $95 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is USPH stock a buy right now?

Of the 7 analysts covering U.S. Physical Therapy, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks U.S. Physical Therapy, Inc. 57 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank USPH?

As at 14 Oct 2026, U.S. Physical Therapy, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (79 of 100).

Will USPH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +14.2% from the last close, and Ticker Nerd's factor model ranks U.S. Physical Therapy, Inc. 57 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the USPH stock forecast for 2030?

No analyst covering U.S. Physical Therapy, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for USPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $95 to $100 over the next 12 months.

How has USPH stock performed over the past year?

U.S. Physical Therapy, Inc. returned -4.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does U.S. Physical Therapy, Inc. do?

U.S. Physical Therapy, Inc.

What is the latest news on USPH?

The most recent item we track (Business Wire, 21 Sept 2026): "U.S. Physical Therapy Announces the Appointment of New Board Member Myra Davis". U.S. Physical Therapy, Inc. announced that its Board of Directors approved the appointment of Myra Davis as a new board member, effective October 1, 2026. Davis currently serves as Executive Vice President and Chief Information Innovation Officer at Texas Children's.

Company

About U.S. Physical Therapy, Inc.

U.S. Physical Therapy, Inc. is a healthcare services company that operates outpatient physical therapy clinics across the United States. The company provides pre- and post-operative rehabilitation, treatment for orthopedic, sports-related, neurologic, and work-related injuries, as well as preventive care for patients recovering from surgery or injury. Its business also includes industrial injury prevention services, which support employers with onsite injury prevention, ergonomic assessments, functional evaluations, and rehabilitation-focused workplace solutions. U.S. Physical Therapy, Inc. also manages physical therapy facilities for third parties, including hospitals and physician groups. Through its clinic network and employer-focused services, the company plays a specialized role in rehabilitation care and occupational health delivery within the broader medical services market.

CEO Mr. Christopher J. Reading · 4,653 employees · United States · https://www.usph.com